Disclosures

Identification and Mitigation of Relevant Financial Relationships

In accordance with The Standards for Integrity and Independence in Accredited Continuing Education promulgated by the Accreditation Council for Continuing Medical Education (“ACCME”), it is the policy of Antidote Education Company that all individuals in a position to control the content of an activity disclose all financial relationships with any ineligible company to Antidote prior to the activity.  A relevant financial relationship is defined as any financial relationship in any amount occurring within the past 24 months with an ineligible company.  A relevant financial relationship exists when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he or she has a financial relationship.  Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Antidote has established mechanisms to mitigate any relevant financial relationships disclosed or otherwise identified to ensure independence in all of its educational activities.  If, through the application of these mechanisms, an individual’s relevant financial relationships cannot be resolved, that individual is prohibited from participating in the activity in question in any manner.

The relevant financial relationships, if any, of the individuals in a position to control the content of this educational activity have been mitigated through Antidote’s conflict resolution mechanism.  Nonetheless, the relevant financial relationships, if any, of each individual in a position to control the content of this educational activity have been disclosed to you in the following section of this handout entitled “Disclosures.”  If an individual has no relevant financial relationships, that fact is also provided to you.

Disclosures

The presenters and planners for this educational activity have disclosed the following relevant financial relationships with ineligible companies:

S. Hinan Ahmed, MD, FACC, FSCAI – Abbott (Consultant); Abbott (Speaker); Medtronic (Speaker); Abbott – Relationship ended

Craig Ainsworth, MD – Tetraphase Pharmaceutical (Speaker)

Allen S. Anderson, MD – Edwards Lifesciences (Consultant); Boehringer Ingelheim, Merck, Novartis, Pfizer (Speaker)

Alison L. Bailey, MD, FACC, FASPC – OptumRX (Consultant)

Sonja Brune, MSN, APRN, CCNS, CHFN, AACC, FHFSA, HF-Cert – Impulse Dynamics and Zoll Medical (Speaker)

Jeffrey DellaVolpe, MD – Fresenius Medical Care, Maquet (Advisor); ExThera Medical, MC3 Cardiopulmonary (Consultant)

Gregory Fontana, MD – Abbott (Consultant); Medtronic (Advisor); Abbott, Edwards, Highlife, Medtronic, Peerbridge, and Pi Cardia (Research funding (if PI or named investigator)

Alan Gass, MD – Abiomed, Abbott (Speaker)

Gerardo Gonzalez-Guardiola, MD – Cook Aortic, Terumo Aortic (Consultant)

Wissam Jaber, MD – Inari Medical, Neptune Medical, RapidAI (Consultant); Medtronic (Advisor); Medtronic, Inari Medical (Research funding – if PI or named investigator)

Parag H. Joshi, MD, MHS – Novartis (Advisor); G3 Therapeutics (Ownership interest (stock or stock options)); Amgen, Kaneka, Novartis, Novo Nordisk (Researcher); Amgen (research) and Novartis (advisor); Amgen and Novartis – Relationships have ended

Chandra Kunavarapu, MD, FACC – Bayer, Inari, Janssen, Merck (Speaker)

Jamil Malik, MD – Chiesi (Consultant and Speaker)

Thomas McLaren, MD – HeartFlow (Consultant)

David Miramontes, MD, FACEP, FAEMS – Purdue Pharma (Consultant)

Ryan Morton, MD – GammaTile (Consultant) – Relationship ended

Andrea Natale, MD, FHRS, FACC, FESC – Abbott, Boston Scientific, Baylis, Biosense Webster, BIOTRONIK, Medtronic (Consultant)

Keith Nguyen, MD, FSCAI – Abiomed, Shockwave (Speaker)

David Pederson, MD – Acutus, Abbott, BioSig, Octogos (Advisor); Boston Scientific, Medtronic (Researcher)

Jeffrey Popma, MD – Medtronic (Executive Role)

Michael Reardon, MD – Abbott, Boston Scientific, Gore, Medtronic (Consultant)

V. Seenu Reddy, MD, MBA, FACS, FACC – 3 M and Medtronic (Advisor); Biomerieux (Consultant); Angiodynamics and Zoll (Speaker)

Robert D. Schaller, DO – Medtonic (Speaker)

Justin Scharwath, B.S. / ACS, RDCS, RVT – Lantheus Medical Imaging (Consultant)

Michael Siah, MD – Abbott, Cagent Medical, CSI, InRoad Medical, Phillips, Shockwave Medical (Consultant)

Nandish Thukral, MD, FSCAI – Abiomed, Chiesi, Janssen, and Penumbra (Speaker)

Lorraine Ware, MD – Arrowhead Pharmaceuticals, Akebia Therapeutics, Global Blood Therapeutics/Pfizer, Santhera (Consultant); Genentech (Research funding (if PI or named investigator); Boehringer Ingelheim (Independent contractor); Boehringer Ingelheim and Santhera (Relationships Ended)

Randal White, MD, FACC – Pfizer (Speaker)

Rolando Zamora, MD – Edwards (Consultant)
Thomas Zgonis, DPM, FACFAS – Orthofix (Consultant); Wolter Kluwer (Royalties or patent beneficiary)

All of the relevant financial relationships listed for these individuals listed above have been mitigated.

None of the other presenters, planners, and reviewers of this educational activity have relevant financial relationship(s) to disclose with ineligible companies.